Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer.
|
31139014 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, FN1, TIMP1, MMP2, and SPARC are correlated with SERPINE1 and may serve as therapeutic targets in reversing EMT in GC.
|
31218131 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis of SPARC expression was performed in 117 surgically resected GC specimens, and the localization of SPARC positive cells, as well as the rassociation between SPARC expression and clinicopathological characteristics were evaluated.
|
29403557 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The investigations of SERPINE1 and SPARC may promote their predictive and prognostic value in GC.
|
30410354 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility.
|
28962925 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Western blotting and immunofluorescence staining were applied for verifying the endogenous expression of SPARC in human cell lines of gastric cancer and fibroblast.
|
29156791 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
SPARC suppressed the invasion and migration of GC by reducing MMP-7, MMP-9, N-cadherin, Sp1 and p-ERK1/2 expression.
|
24676680 |
2014 |
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence.
|
22491017 |
2013 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the SPARC gene may be a useful independent predictor of outcomes in patients with gastric cancer.
|
24018911 |
2013 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, targeting of SPARC could be an effective therapeutic approach against gastric cancer.
|
20525171 |
2010 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among these 9 genes, expression of versican and osteonectin was investigated in greater detail using immunohistochemistry in 116 GCs from 64 exposed and 52 nonexposed patients who developed GC after the bombing.
|
19058179 |
2009 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secreted Protein, Acidic and Rich in Cysteine (SPARC) (Osteonectins), one of the most highly expressed genes in both intestinal and diffuse gastric cancers in our microarray results, was selected for further study.
|
15558074 |
2004 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present results suggest that osteonectin is highly expressed in reactive stroma associated with invasive differentiated adenocarcinomas and that it may serve as a useful clinical diagnostic marker for stomach cancer.
|
12104055 |
2002 |